Assessment of sociodemographic and psychiatric characteristics of transgender adults seen at a Midwest tertiary medical center.


Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2024
Historique:
received: 07 06 2024
accepted: 13 08 2024
medline: 19 9 2024
pubmed: 19 9 2024
entrez: 19 9 2024
Statut: epublish

Résumé

The National Academy of Medicine has formally identified transgender adults as an understudied population in critical need of health research. While national surveys, like the US Transgender survey, have characterized higher rates of depression, anxiety, suicidality and socioeconomic need in the transgender community, studies have not examined the impact of sociodemographic and clinical characteristics on mental health related outcomes. To describe the sociodemographic and mental health characteristics of transgender adults seen at a large Midwest transgender clinic and to determine factors associated with self-reported mental health conditions. Descriptive, retrospective, cross-sectional study of new transgender patients 18 years and older seen at a large Midwest transgender clinic between December 2019 and June 2022. A total of 482 charts were reviewed. During their initial evaluation, 11.6% (56/482) reported having a history of suicide attempt and 81.3% (392/482) reported a mental health diagnosis with the most common being depression, anxiety, attention deficit disorder, and post-traumatic stress disorder. Multivariable logistic regression results show no single factor was significantly associated with mental health diagnosis after adjusting for the effect of age and race. Patients who were new to gender affirming hormone therapy (54%, 254/468) are 2.0 (95% CI 1.4-2.9) times more likely to report having a mental health care provider than patients who were seen for continuation of therapy (46%, 214/468). Ten records with race not disclosed, 3 records with gender identity "other" and 2 records with gender identity not disclosed were excluded from analysis. This study reinforces the finding that transgender adults have an increased lifetime prevalence of mental health conditions. The higher prevalence of mental health conditions in our clinic was not associated with sociodemographic factors included in the study. Furthermore, transgender patients are less likely to have seen mental healthcare providers after initiation of gender affirming hormone therapy.

Sections du résumé

Background UNASSIGNED
The National Academy of Medicine has formally identified transgender adults as an understudied population in critical need of health research. While national surveys, like the US Transgender survey, have characterized higher rates of depression, anxiety, suicidality and socioeconomic need in the transgender community, studies have not examined the impact of sociodemographic and clinical characteristics on mental health related outcomes.
Objective UNASSIGNED
To describe the sociodemographic and mental health characteristics of transgender adults seen at a large Midwest transgender clinic and to determine factors associated with self-reported mental health conditions.
Methods UNASSIGNED
Descriptive, retrospective, cross-sectional study of new transgender patients 18 years and older seen at a large Midwest transgender clinic between December 2019 and June 2022.
Results UNASSIGNED
A total of 482 charts were reviewed. During their initial evaluation, 11.6% (56/482) reported having a history of suicide attempt and 81.3% (392/482) reported a mental health diagnosis with the most common being depression, anxiety, attention deficit disorder, and post-traumatic stress disorder. Multivariable logistic regression results show no single factor was significantly associated with mental health diagnosis after adjusting for the effect of age and race. Patients who were new to gender affirming hormone therapy (54%, 254/468) are 2.0 (95% CI 1.4-2.9) times more likely to report having a mental health care provider than patients who were seen for continuation of therapy (46%, 214/468). Ten records with race not disclosed, 3 records with gender identity "other" and 2 records with gender identity not disclosed were excluded from analysis.
Conclusion UNASSIGNED
This study reinforces the finding that transgender adults have an increased lifetime prevalence of mental health conditions. The higher prevalence of mental health conditions in our clinic was not associated with sociodemographic factors included in the study. Furthermore, transgender patients are less likely to have seen mental healthcare providers after initiation of gender affirming hormone therapy.

Identifiants

pubmed: 39296718
doi: 10.3389/fendo.2024.1445679
pmc: PMC11408213
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1445679

Informations de copyright

Copyright © 2024 Cortez, Moog, Baranski, Williams, Wang, Nicol, Baranski and Herrick.

Déclaration de conflit d'intérêts

CH is a consultant for Teladoc Health. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Samuel Cortez (S)

Department of Pediatrics, Division of Endocrinology and Diabetes, Washington University School of Medicine, Saint Louis, MO, United States.

Dominic Moog (D)

Washington University School of Medicine, Saint Louis, MO, United States.

Elizabeth Baranski (E)

Department of Medicine, Division of Endocrinology, Diabetes, and Lipid Research, Washington University School of Medicine, Saint Louis, MO, United States.

Kelley Williams (K)

Department of Medicine, Division of Endocrinology, Diabetes, and Lipid Research, Washington University School of Medicine, Saint Louis, MO, United States.

Jinli Wang (J)

Center for Biostatistics and Data Science, Washington University School of Medicine, Saint Louis, MO, United States.

Ginger Nicol (G)

Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, United States.

Thomas Baranski (T)

Department of Medicine, Division of Endocrinology, Diabetes, and Lipid Research, Washington University School of Medicine, Saint Louis, MO, United States.

Cynthia J Herrick (CJ)

Department of Medicine, Division of Endocrinology, Diabetes, and Lipid Research, Washington University School of Medicine, Saint Louis, MO, United States.
Department of Surgery, Division of Public Health Sciences, Washington University School of Medicine, Saint. Louis, MO, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH